Top Markets
#1 GEKKO GEKKO +53.94%
#2 ADO Protocol ADO Protocol +38.79%
#3 Pons Pons +37.50%
#4 Prom Prom +32.61%
#5 Helium Helium +28.33%
#6 TENDIES TENDIES +25.51%
#7 Giggle Fund Giggle Fund +18.81%
#8 龙虾 (Lobster) 龙虾 (Lobster) +18.72%
#9 Main Street Yield Main Street Yield +17.48%
#10 o1.exchange o1.exchange +17.29%
Coin of the day
GEKKO GEKKO
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
Kedudukan dalam Saham #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Harga Saham
$4.74
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$1.12B
Perubahan (1 hari)
-5.77%
Perubahan (1 tahun)
-16.96%
Negara
FR
Perdagangan Inventiva S.A. (IVA)

Kategori

Healthcare
Hasil untuk Inventiva S.A. (IVA)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Inventiva S.A., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Inventiva S.A. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH